Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6554047 | 0.89 | GPR3 (0.34) | GPR3BCHEACHEHTR2A | |
| Hydrochloric Acid SCHEMBL5689271 | 0.81 | GPR3 (0.31) | GPR3HTR2A | |
| Hydrochloric Acid SCHEMBL3684750 | 0.77 | ADRA2C (0.32) | — | |
| Hydrochloric Acid SCHEMBL29216496 | 0.77 | PDCD1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL4268434 | 0.75 | MAPK1 (0.32) | GPR3HTR2A | |
| Hydrochloric Acid SCHEMBL8857687 | 0.75 | GPR3 (0.31) | GPR3 | |
| Hydrochloric Acid SCHEMBL5595927 | 0.75 | PTPN1 (0.39) | GPR3 | |
| Hydrochloric Acid SCHEMBL911069 | 0.72 | GPR3 (0.35) | GPR3HTR2A | |
| Hydrochloric Acid SCHEMBL14735449 | 0.72 | GPR3 (0.35) | GPR3HTR2A | |
| Hydrochloric Acid SCHEMBL6908726 | 0.72 | GPR3 (0.35) | GPR3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324995-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-06-27 | — | — | US | claimed |
| WO-2002026729-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-04-04 | — | — | WO | claimed |
| CN-106459246-B | Process for producing olefin polymer, catalyst for olefin polymerization, and olefin polymer | 出光兴产株式会社 | 2020-04-10 | — | — | CN | disclosed |
| US-20140256997-A1 | 1-OCTENE, 1-DECENE, 1-DODECENE TERNARY COPOLYMER AND LUBRICANT COMPOSITION CONTAINING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2746302-A1 | OLEFIN OLIGOMER AND PRODUCTION METHOD THEREOF | Idemitsu Kosan Co., Ltd (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-1260525-B1 | 1-BUTENE POLYMER AND MOLDED PRODUCT CONSISTING OF THE POLYMER | IDEMITSU KOSAN CO (JP) | 2012-12-12 | — | — | EP | disclosed |
| EP-2264077-B1 | 1-Butene based polymer and the product formed therefrom | IDEMITSU KOSAN CO (JP) | 2012-06-13 | — | — | EP | disclosed |
| EP-2264077-A1 | 1-Butene based polymer and the product formed therefrom | Idemitsu Kosan Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-1659135-B1 | CHLORINATED PROPYLENE POLYMER, PROCESS FOR PRODUCING THE SAME, AND USE OF THE SAME | IDEMITSU KOSAN CO (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1368388-B1 | DUAL-SITE OLEFIN POLYMERISATION CATALYST COMPOSITION | BOREALIS TECH OY (FI) | 2009-03-04 | — | — | EP | disclosed |
| EP-1260525-A1 | 1-BUTENE POLYMER AND MOLDED PRODUCT CONSISTING OF THE POLYMER | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| US-20020143113-A1 | Process for producing a polymer of an alpha-olefin and lubricant | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| WO-2002060963-A1 | DUAL-SITE OLEFIN POLYMERISATION CATALYST COMPOSITION | BOREALIS TECHNOLOGY OY (FI) | 2002-08-08 | — | — | WO | disclosed |
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-06-27 | — | — | US | disclosed |
| US-6376418-B1 | COORDINATION CATALYSTS | FINA TECHNOLOGY, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2002026729-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-1164146-A2 | Process for producing a polymer of an alpha-olefin and lubricant | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6114480-A | CATALYST COMPRISES A METALLOCENE COMPOUND; PRODUCES CRYSTALLINE OR ATACTIC POLYMER WITH A LOW MOLECULAR WEIGHT AND NARROW OR BROAD MOLECULAR WEIGHT DISTRIBUTION | FINA TECHNOLOGY, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0802206-A2 | Process and catalyst for producing polyolefins having low molecular weight | FINA TECHNOLOGY, INC. (US) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | PPARD, PPARA, PPARG | ACHE 4464/4885GPR3 1150/4885BCHE 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.